Compare Invesco DB Agriculture Fund (DBA) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Quest Diagnostics Inc — how do they compare? Invesco DB Agriculture Fund trades at $27.6, while Quest Diagnostics Inc trades at $205.45 (market cap $22.80B). The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Invesco DB Agriculture Fund pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Invesco DB Agriculture Fund nearer its low. Which is the better fit depends on your goals.
| DBA | DGX | |
|---|---|---|
52-Week High | $28.73 | $216.02 |
52-Week Low | $25.44 | $166.42 |
Market Cap | — | $22.80B |
Sector | — | Health |
Enterprise Value | — | $28.82B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund) trades at $27.72, down 0.18% with a bullish technical signal supported by moving averages. The ETF tracks agricultural commodities including corn, soybeans, and livestock. Recent news highlights supply disruptions in Brazil's coffee harvest and China's $17 billion U.S. crop purchase commitment through 2028, potentially benefiting agricultural ETFs.
The fund offers exposure to rising commodity prices driven by supply constraints and geopolitical factors, but faces volatility from weather patterns and global demand shifts. Key risks include commodity price fluctuations and concentrated agricultural exposure. Analyst sentiment is mixed with technical indicators showing strength but overbought conditions on shorter-term RSI.
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
